-
First patient dosed in 68 patient Randomised Phase 2 HER-Vaxx cancer trial
-
Two Eastern European sites now actively recruiting
-
Approval imminent for trial sites in Hong Kong, Taiwan, Thailand and India
SYDNEY, Australia, 14 March 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced dosing of the first patient in an open-label, randomised multi-centre Phase 2 study with its HER-Vaxx (IMU-131) cancer vaccine for the treatment of HER-2 positive gastric cancer patients.
For further information please download PDF attached:
Download this document
